stockrow
Saturday 7 November 2026
Export CELZ’s income statement to Excel — free account
Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +14.6%
- Free cash flow
- −27.1%
Quarter to June 2026, against a year earlier
0.62
0.01
+1.64%
Follow CELZ
Alert me
Creative Medical Technology Holdings, Inc. (CELZ) P/E ratio
Creative Medical Technology Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.6× (March 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.6×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | n/m |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| AZTR Azitra, Inc. compare | 1.3× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)